Real-World Analysis Shows Promising Outcomes, Safety With Ibrutinib in CLL
A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field.
A 2-year follow-up study showed that ibrutinib maintained efficacy and safety among patients with chronic lymphocytic leukemia, highlighting its importance in the field.
Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report five-year outcomes…
In a clinical trial, rusfertide cut the number of phlebotomies people with polycythemia vera (PCV) needed from nine to less than one per year.
Vincent Law says researchers on the verge of huge discoveries in treating brain tumors
Investigators have explored whether bariatric surgery may be associated with a reduced risk of breast cancer in female patients with obesity and/or hyperinsulinemia at the…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.
Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being…
Women who are 65 years old or older with high-risk breast cancer and are treated with chemotherapy are more likely to develop a substantial decline…
Chang-Tsu Yuan, Wei-Li Ma; Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor. Blood 2024; 143 (20):…
Tumor mutational load is a strong prognostic factor for progression to therapy among individuals with HCMBL, independent of CLL-IPI.Accounting for both CLL